TriSalus (TLSI) Director Kerry Hicks Receives 15k-Share Option Grant

Rhea-AI Filing Summary

Form 4 filing overview: On 06/12/2025, TriSalus Life Sciences, Inc. (TLSI) director Kerry R. Hicks was granted a non-qualified stock option for 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on 06/11/2035 and will vest in full on the earlier of 06/12/2026 or the company’s next annual shareholder meeting, subject to continued board service.

Following the grant, Mr. Hicks now beneficially owns 89,222 derivative securities (principally stock options). The filing indicates direct ownership; no indirect holdings were reported. No purchases or sales of common stock occurred, and the filing does not disclose any change to Mr. Hicks’ non-derivative share count.

The transaction was coded “A” (acquisition), routine for director compensation, and was not executed under a Rule 10b5-1 plan. Because the filing relates only to an option grant—without an accompanying open-market trade—its immediate market impact is typically limited. Nevertheless, investors may view the award as modest alignment of director incentives with shareholder interests through long-dated equity compensation.

Insights

Securities Analyst

TL;DR: Routine director option grant; neutral impact on valuation.

The 15,000-share option awarded to director Kerry Hicks at $5.50 strikes me as standard board compensation. It represents a small fraction of TLSI’s outstanding shares and is unlikely to exert material dilution even if fully exercised. Because no shares were bought or sold in the open market, the filing sends neither bullish nor bearish signals. Investors should simply note the updated beneficial ownership—89,222 derivative securities—when tracking insider alignment, but I would not adjust earnings models or target price on this news.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HICKS KERRY R

(Last) (First) (Middle)

851 EAGLES PASS RD

(Street)

EVERGREEN CO 80439

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.5	06/12/2025		A		15,000		(1)	06/11/2035	Common Stock	15,000	$0	89,222	D

Explanation of Responses:

1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TLSI report on 06/12/2025?

Director Kerry R. Hicks received an option grant for 15,000 shares at a $5.50 exercise price.

When will the 15,000-share option granted to Kerry Hicks vest?

The option vests fully on 06/12/2026 or on the date of TLSI’s next annual shareholder meeting, whichever comes first.

What is the total number of derivative securities Kerry Hicks owns after the transaction?

After the grant, Hicks beneficially owns 89,222 derivative securities.

Did the Form 4 report any open-market purchase or sale of TLSI common stock?

No. The filing only disclosed an option acquisition; no common shares were bought or sold.

What is the expiration date of the newly granted stock option?

The option expires on 06/11/2035.